BeiGene, Ltd. (NASDAQ:BGNE) Given Average Rating of “Moderate Buy” by Brokerages

BeiGene, Ltd. (NASDAQ:BGNE) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $246.21.

A number of analysts have issued reports on the company. Bank of America decreased their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research note on Tuesday, July 9th. Citigroup lifted their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Finally, JMP Securities assumed coverage on BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price objective on the stock.

BeiGene Trading Up 1.5 %

BeiGene stock opened at $207.25 on Tuesday. The stock has a market cap of $20.17 billion, a PE ratio of -40.80 and a beta of 0.63. The stock has a 50-day moving average price of $211.76 and a 200 day moving average price of $178.98. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. During the same period last year, the company earned ($3.64) EPS. The firm’s quarterly revenue was up 56.1% on a year-over-year basis. Equities research analysts predict that BeiGene will post -5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BeiGene news, CEO John Oyler sold 6,175 shares of BeiGene stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider Titus B. Ball sold 137 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Oyler sold 6,175 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. Insiders have sold 23,070 shares of company stock worth $4,901,050 in the last three months. 7.43% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its holdings in shares of BeiGene by 156.3% in the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after buying an additional 75 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of BeiGene in the third quarter valued at $36,000. Headlands Technologies LLC acquired a new stake in shares of BeiGene in the first quarter valued at $50,000. SG Americas Securities LLC acquired a new stake in shares of BeiGene in the third quarter valued at $105,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of BeiGene by 204.1% in the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after buying an additional 849 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.